Advertisement

Picture Demy-Colton BioFuture 2021 NYC D Meet Top Investors 650x300px
Organisation › Details

Exelixis Inc. (Nasdaq: EXEL)

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. *

 

Period Start 1994-01-01 established
Period End 1998-09-17 existent
Product Industry biopharmaceutical
     
Region Region South San Francisco, CA
  Country United States (USA)
  Street 210 East Grand Avenue
  City 94083-0511 South San Francisco, CA
  Tel +1-650-837-7000
    Address record changed: 2020-12-02
     
Basic data Employees n. a.
  Currency USD
  Annual sales 113,470,000 (revenues, total, consolidated (2007) 2006-12-31)
  Profit -86,381,000 (2007-12-31)
  Cash 299,530,000 (2007-12-31)
     
    * Document for �About Section�: 
     
   
Record changed: 2021-02-12

Advertisement

Picture [iito] Plain Stupid Simple 650x80px

More documents for Exelixis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

Picture Demy-Colton BioFuture 2021 NYC B Preview Download 650x300px




» top